SCHEMBL12350484

SCHEMBL12350484

C[C@@H]1CN(C2CCC2)CCN1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.36
BIRC2 Q13490 1/20 0.36
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
DPP4 P27487 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14856418 1.00 HTR6 (0.36) HTR6BIRC2CYP2C9TSHRCYP2C19
Hydrochloric Acid SCHEMBL2237196 0.98 HTR6 (0.35) HTR6BIRC2CYP2C9TSHRCYP2C19
SCHEMBL6582291 0.94 HTR6 (0.39) HTR6BIRC2DPP4MEN1KMT2A
SCHEMBL6582294 0.94 HTR6 (0.39) HTR6BIRC2DPP4MEN1KMT2A
SCHEMBL23139621 0.91 BIRC2 (0.34) HTR6BIRC2KMT2A
SCHEMBL25698895 0.91 BIRC2 (0.34) HTR6BIRC2KMT2A
Hydrochloric Acid SCHEMBL25337896 0.89 HPGD (0.34) BIRC2KMT2AALDH1A1
Hydrochloric Acid SCHEMBL25337894 0.89 HPGD (0.34) BIRC2KMT2AALDH1A1
SCHEMBL17484304 0.85 HPGD (0.33) HTR6BIRC2KMT2A
SCHEMBL15933081 0.83 ALDH1A1 (0.42) BIRC2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150164888-A1 CYCLOPROPYL AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2015-06-18 US disclosed
US-20150164889-A1 CYCLOPROPYL AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2015-06-18 US disclosed
US-20150164888-A1 CYCLOPROPYL AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2015-06-18 US disclosed
US-20150164889-A1 CYCLOPROPYL AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2015-06-18 US disclosed
US-9012452-B2 Processes for making cyclopropyl amide derivatives and intermediates associated therewith ASTRAZENECA AB (SE) 2015-04-21 US disclosed
US-9012452-B2 Processes for making cyclopropyl amide derivatives and intermediates associated therewith ASTRAZENECA AB (SE) 2015-04-21 US disclosed
EP-2536685-B1 PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH ASTRAZENECA AB (SE) 2015-04-08 EP disclosed
US-8993577-B2 Cyclopropyl amide derivatives ASTRAZENECA AB (SE) 2015-03-31 US disclosed
US-8993577-B2 Cyclopropyl amide derivatives ASTRAZENECA AB (SE) 2015-03-31 US disclosed
US-20130172560-A1 PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH ASTRAZENECA AB (SE) 2013-07-04 US disclosed
US-20130172560-A1 PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH ASTRAZENECA AB (SE) 2013-07-04 US disclosed
EP-2398780-B1 CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR ASTRAZENECA AB (SE) 2013-04-17 EP disclosed
EP-2398780-B1 CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR ASTRAZENECA AB (SE) 2013-04-17 EP disclosed
WO-2011102794-A1 PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH ASTRAZENECA AB (SE) 2011-08-25 WO disclosed
WO-2011102793-A1 SOLID FORMS COMPRISING A CYCLOPROPYL AMIDE DERIVATIVE ASTRAZENECA AB (SE) 2011-08-25 WO disclosed
US-20110201622-A1 Solid Forms Comprising A Cyclopropyl Amide Derivative ASTRAZENECA PHARMACEUTICALS LP 2011-08-18 US disclosed
US-20100216812-A1 Cyclopropyl Amide Derivatives ASTRAZENECA AB (SE) 2010-08-26 US disclosed
US-20100216812-A1 Cyclopropyl Amide Derivatives ASTRAZENECA AB (SE) 2010-08-26 US disclosed
WO-2010096011-A1 CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR ASTRAZENECA AB (SE) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201622-A1 Solid Forms Comprising A Cyclopropyl Amide Derivative SFPQ, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SBDS HTR6 3827/4885BIRC2 3074/4885CYP2C9 115/4885
US-20130172560-A1 PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH HRH4, HRH2, HRH3 HTR6 209/4885BIRC2 4817/4885CYP2C9 198/4885
US-20100216812-A1 Cyclopropyl Amide Derivatives HRH4, HRH2, HRH3 HTR6 88/4885BIRC2 3544/4885CYP2C9 3178/4885
US-20150164888-A1 CYCLOPROPYL AMIDE DERIVATIVES HRH4, HRH2, HRH3 HTR6 88/4885BIRC2 3544/4885CYP2C9 3178/4885
US-20150164889-A1 CYCLOPROPYL AMIDE DERIVATIVES HRH4, HRH2, HRH3 HTR6 88/4885BIRC2 3544/4885CYP2C9 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.